Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ahmad Abdel Halim

Internal Medicine Flint, MI Medical Doctor

NPI 1649312828 CMS profile 210646

G1071 N Ballenger Hwy, Park Plaza Suite 311, Flint, MI 48504

Open in the dashboard

General payments

$5,108

261 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmad Abdel Halim of Flint, MI is reported in the CMS Open Payments database as having received $5,108 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,600 96
2024 General $1,056 60
2023 General $1,768 67
2022 General $684 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmad Abdel Halim
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ahmad Abdel Halim were reported at $1,600. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ahmad Abdel Halim Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $684 $141 $42–$496 $149
2023 $1,768 $149 $45–$519 $160
2024 $1,056 $154 $47–$537 $164
2025 $1,600 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Pfizer Inc. $773 47 payments
  2. Cook Medical LLC $617 7 payments
  3. AbbVie, Inc. $537 38 payments
  4. Novo Nordisk Inc $484 32 payments
  5. Amgen Inc. $337 19 payments
  6. GlaxoSmithKline, LLC. $332 17 payments
  7. Abbott Laboratories $197 10 payments
  8. Novartis Pharmaceuticals Corporation $180 8 payments
  9. Sumitomo Pharma America, Inc. $147 10 payments
  10. Exact Sciences Corporation $135 7 payments
  11. Other $1,370 66 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,717 260 payments
  2. Travel and Lodging $391 1 payment
Products named General payments · program years 2022–2025
  1. NURTEC ODT $706 43 payments
  2. Cook $617 7 payments
  3. ELIQUIS $452 25 payments
  4. Ozempic $426 28 payments
  5. RYBELSUS $426 28 payments
  6. Otezla $278 16 payments
  7. UBRELVY $271 21 payments
  8. ZAVZPRET $264 19 payments
  9. PAXLOVID $249 15 payments
  10. TRELEGY ELLIPTA $225 15 payments
  11. Other $3,049 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 223 drugs

Part D claims

25,292

Median for Internal Medicine: 777

Drug cost

$2,718,325

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 494 $600,131
Ozempic Semaglutide Brand 167 $309,419
Mounjaro Tirzepatide Brand 124 $183,611
Xarelto Rivaroxaban Brand 110 $152,212
Trulicity Dulaglutide Brand 68 $136,710
Januvia Sitagliptin Phosphate Brand 96 $122,596
Rybelsus Semaglutide Brand 61 $100,383
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $74,971
Entresto Sacubitril/Valsartan Brand 53 $66,043
Xifaxan Rifaximin Brand 19 $56,208

The 10 drugs with the highest cost, of 223 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$437,045

Of which drugs: $12,333

Medicare patients

868

Average age 76

Services billed

23,619

494 women, 374 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 41%
Diabetes 39%
Chronic kidney disease 38%
Heart failure 36%
Atrial fibrillation 33%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 126 126 $10,309
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 68 588 $466
Injection, ketorolac tromethamine, per 15 mg J1885 Office 31 104 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $108
$108 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $84
$84 — —
ELIQUIS
  • PFIZER INC. $65
  • E.R. Squibb & Sons, L.L.C. $16
$81 494 —
RYBELSUS
  • Novo Nordisk Inc $60
$60 61 —
Ozempic
  • Novo Nordisk Inc $60
$60 167 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record